Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PHIBRO ANIMAL HEALTH CORPPAHC · Entity 4671 | Director · President and CEO | August 06, 2026 | August 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PHIBRO ANIMAL HEALTH CORP
Report date August 06, 2026 · Filed August 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 15,177 |
Reported balance
After 2026-08-06 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-06 · Grant · Acquired 11,699 · Balance 15,177 F1: The reported securities represent restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of Class A Common Stock. F2: The RSUs vest in substantially equal installments on each of the first three anniversaries of August 1, 2026, subject to the Reporting Person's continued employment through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities represent restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of Class A Common Stock.
F2: The RSUs vest in substantially equal installments on each of the first three anniversaries of August 1, 2026, subject to the Reporting Person's continued employment through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 12, 2018 Filed Sep 15, 2018 01:04 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionClass A Common Stock | 2,500 | $11.83 | $29,575.00 |
DisclosureSEC source: 0001144204-18-049580 · tv502926_4.xml · nonDerivative · entry 1 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2018, as amended on September 12, 2018. Read SEC document |
| March 12, 2018 Filed Mar 13, 2018 01:11 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionOption to purchase Common Stock · Derivative | 13,162 | $0.00 Strike: $11.83 | $0.00 |
DisclosureSEC source: 0001144204-18-014217 · tv488170_4.xml · derivative · entry 9 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 13,162 shares Expires 2019-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 7, 2017. Read SEC document |
| March 12, 2018 Filed Mar 13, 2018 01:11 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 13,162 | $40.00 | $526,480.00 |
DisclosureSEC source: 0001144204-18-014217 · tv488170_4.xml · nonDerivative · entry 6 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 7, 2017. Read SEC document |
| March 12, 2018 Filed Mar 13, 2018 01:11 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionClass A Common Stock | 13,162 | $11.83 | $155,706.46 |
DisclosureSEC source: 0001144204-18-014217 · tv488170_4.xml · nonDerivative · entry 5 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,162 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 7, 2017. Read SEC document |
| March 09, 2018 Filed Mar 13, 2018 01:11 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionOption to purchase Common Stock · Derivative | 6,576 | $0.00 Strike: $11.83 | $0.00 |
DisclosureSEC source: 0001144204-18-014217 · tv488170_4.xml · derivative · entry 8 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,162 Underlying: Class A Common Stock · 6,576 shares Expires 2019-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 7, 2017. Read SEC document |
| March 09, 2018 Filed Mar 13, 2018 01:11 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 6,576 | $40.03 | $263,237.28 |
DisclosureSEC source: 0001144204-18-014217 · tv488170_4.xml · nonDerivative · entry 4 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 7, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.10, inclusive. Read SEC document |
| March 09, 2018 Filed Mar 13, 2018 01:11 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionClass A Common Stock | 6,576 | $11.83 | $77,794.08 |
DisclosureSEC source: 0001144204-18-014217 · tv488170_4.xml · nonDerivative · entry 3 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,576 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 7, 2017. Read SEC document |
| March 08, 2018 Filed Mar 13, 2018 01:11 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionOption to purchase Common Stock · Derivative | 3,425 | $0.00 Strike: $11.83 | $0.00 |
DisclosureSEC source: 0001144204-18-014217 · tv488170_4.xml · derivative · entry 7 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,738 Underlying: Class A Common Stock · 3,425 shares Expires 2019-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 7, 2017. Read SEC document |
| March 08, 2018 Filed Mar 13, 2018 01:11 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 3,425 | $40.00 | $137,000.00 |
DisclosureSEC source: 0001144204-18-014217 · tv488170_4.xml · nonDerivative · entry 2 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 7, 2017. Read SEC document |
| March 08, 2018 Filed Mar 13, 2018 01:11 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionClass A Common Stock | 3,425 | $11.83 | $40,517.75 |
DisclosureSEC source: 0001144204-18-014217 · tv488170_4.xml · nonDerivative · entry 1 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,425 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 7, 2017. Read SEC document |
| March 06, 2018 Filed Mar 8, 2018 02:47 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionOption to purchase Common Stock · Derivative | 100 | $0.00 Strike: $11.83 | $0.00 |
DisclosureSEC source: 0001144204-18-013456 · tv488031_4.xml · derivative · entry 6 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,163 Underlying: Class A Common Stock · 100 shares Expires 2019-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 7, 2017. Read SEC document |
| March 06, 2018 Filed Mar 8, 2018 02:47 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 100 | $40.15 | $4,015.00 |
DisclosureSEC source: 0001144204-18-013456 · tv488031_4.xml · nonDerivative · entry 4 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 7, 2017. Read SEC document |
| March 06, 2018 Filed Mar 8, 2018 02:47 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionClass A Common Stock | 100 | $11.83 | $1,183.00 |
DisclosureSEC source: 0001144204-18-013456 · tv488031_4.xml · nonDerivative · entry 3 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 7, 2017. Read SEC document |
| March 05, 2018 Filed Mar 8, 2018 02:47 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionOption to purchase Common Stock · Derivative | 3,860 | $0.00 Strike: $11.83 | $0.00 |
DisclosureSEC source: 0001144204-18-013456 · tv488031_4.xml · derivative · entry 5 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,263 Underlying: Class A Common Stock · 3,860 shares Expires 2019-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 7, 2017. Read SEC document |
| March 05, 2018 Filed Mar 8, 2018 02:47 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 3,860 | $40.06 | $154,631.60 |
DisclosureSEC source: 0001144204-18-013456 · tv488031_4.xml · nonDerivative · entry 2 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 7, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.15, inclusive. Read SEC document |
| March 05, 2018 Filed Mar 8, 2018 02:47 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionClass A Common Stock | 3,860 | $11.83 | $45,663.80 |
DisclosureSEC source: 0001144204-18-013456 · tv488031_4.xml · nonDerivative · entry 1 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,860 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 7, 2017. Read SEC document |
| August 21, 2017 Filed Aug 22, 2017 01:07 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionOption to purchase Common Stock · Derivative | 800 | $0.00 Strike: $11.83 | $0.00 |
DisclosureSEC source: 0001144204-17-044479 · v473786_form4.xml · derivative · entry 6 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,123 Underlying: Class A Common Stock · 800 shares Expires 2019-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 7, 2017. Read SEC document |
| August 21, 2017 Filed Aug 22, 2017 01:07 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 800 | $40.02 | $32,016.00 |
DisclosureSEC source: 0001144204-17-044479 · v473786_form4.xml · nonDerivative · entry 4 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 7, 2017. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.10, inclusive. Read SEC document |
| August 21, 2017 Filed Aug 22, 2017 01:07 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionClass A Common Stock | 800 | $11.83 | $9,464.00 |
DisclosureSEC source: 0001144204-17-044479 · v473786_form4.xml · nonDerivative · entry 3 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 7, 2017. Read SEC document |
| August 17, 2017 Filed Aug 22, 2017 01:07 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionOption to purchase Common Stock · Derivative | 4,176 | $0.00 Strike: $11.83 | $0.00 |
DisclosureSEC source: 0001144204-17-044479 · v473786_form4.xml · derivative · entry 5 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,923 Underlying: Class A Common Stock · 4,176 shares Expires 2019-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 7, 2017. Read SEC document |
| August 17, 2017 Filed Aug 22, 2017 01:07 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 4,176 | $40.01 | $167,081.76 |
DisclosureSEC source: 0001144204-17-044479 · v473786_form4.xml · nonDerivative · entry 2 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 7, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.15, inclusive. Read SEC document |
| August 17, 2017 Filed Aug 22, 2017 01:07 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionClass A Common Stock | 4,176 | $11.83 | $49,402.08 |
DisclosureSEC source: 0001144204-17-044479 · v473786_form4.xml · nonDerivative · entry 1 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,176 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 7, 2017. Read SEC document |
| August 16, 2017 Filed Aug 17, 2017 01:07 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionOption to purchase Common Stock · Derivative | 5,938 | $0.00 Strike: $11.83 | $0.00 |
DisclosureSEC source: 0001144204-17-043763 · v473493_form4.xml · derivative · entry 9 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,099 Underlying: Class A Common Stock · 5,938 shares Expires 2019-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 7, 2017. Read SEC document |
| August 16, 2017 Filed Aug 17, 2017 01:07 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 5,938 | $40.04 | $237,757.52 |
DisclosureSEC source: 0001144204-17-043763 · v473493_form4.xml · nonDerivative · entry 6 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 7, 2017. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.13, inclusive. Read SEC document |
| August 16, 2017 Filed Aug 17, 2017 01:07 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionClass A Common Stock | 5,938 | $11.83 | $70,246.54 |
DisclosureSEC source: 0001144204-17-043763 · v473493_form4.xml · nonDerivative · entry 5 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,938 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 7, 2017. Read SEC document |
| August 15, 2017 Filed Aug 17, 2017 01:07 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionOption to purchase Common Stock · Derivative | 1,443 | $0.00 Strike: $11.83 | $0.00 |
DisclosureSEC source: 0001144204-17-043763 · v473493_form4.xml · derivative · entry 8 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,037 Underlying: Class A Common Stock · 1,443 shares Expires 2019-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 7, 2017. Read SEC document |
| August 15, 2017 Filed Aug 17, 2017 01:07 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 1,443 | $40.05 | $57,792.15 |
DisclosureSEC source: 0001144204-17-043763 · v473493_form4.xml · nonDerivative · entry 4 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 7, 2017. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.15, inclusive. Read SEC document |
| August 15, 2017 Filed Aug 17, 2017 01:07 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionClass A Common Stock | 1,443 | $11.83 | $17,070.69 |
DisclosureSEC source: 0001144204-17-043763 · v473493_form4.xml · nonDerivative · entry 3 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,443 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 7, 2017. Read SEC document |
| August 14, 2017 Filed Aug 17, 2017 01:07 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionOption to purchase Common Stock · Derivative | 300 | $0.00 Strike: $11.83 | $0.00 |
DisclosureSEC source: 0001144204-17-043763 · v473493_form4.xml · derivative · entry 7 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,480 Underlying: Class A Common Stock · 300 shares Expires 2019-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 7, 2017. Read SEC document |
| August 14, 2017 Filed Aug 17, 2017 01:07 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 300 | $40.08 | $12,024.00 |
DisclosureSEC source: 0001144204-17-043763 · v473493_form4.xml · nonDerivative · entry 2 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 7, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.25, inclusive. Read SEC document |
| August 14, 2017 Filed Aug 17, 2017 01:07 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionClass A Common Stock | 300 | $11.83 | $3,549.00 |
DisclosureSEC source: 0001144204-17-043763 · v473493_form4.xml · nonDerivative · entry 1 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 7, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.